The Medicines Company

The Medicines — Medicines — Investor Presentation (November 2010)

29 slides from The Medicines's investor presentation, Nov 22, 2010

  1. Slide 1: The Medicines Company Investor Update November 2010

    THE MEDICINES COMPANY Investor Update November 2010

  2. Slide 2: Safe harbor: Forward looking statements

    Safe harbor Forward looking statements Statements contained in these slides about The Medicines Company (the "Company"), the Company's projected revenues and financial results, the Company's products and product candidates, and the timing of clinical trial results, regulatory submissions, product or

  3. Slide 3: Acute / intensive care hospital medicine

    Acute | intensive care hospital medicine Expanding acute episodes, concentration of care facilities, rising demand worldwide

  4. Slide 4: Acute / intensive care hospital medicine is an attractive market

    Acute | intensive care hospital medicine is an attractive market Expanding global acute episodes, concentration of care facilities, rising demand Ischemic heart disease (#1), stroke (#2), and serious hospital infections (~#10) will remain among the leading causes of death, morbidity and hospital cos

  5. Slide 5: Unique time to invest in MDCO

    Unique time to invest in MDCO Opportunity to participate in growth of acute | intensive care hospital medicine worldwide 1. Established | expanding | presence Angiomax(r) (bivalirudin) a growing $400M+ franchise in acute hospital arterial anticoagulation 45% CAGR since launch - >3 million PCI patien

  6. Slide 6: MDCO established and expanding presence in acute / intensive hospital medicine

    MDCO | established | expanding | presence in acute | intensive hospital medicine Focused business plan | Angiomax $400M+ franchise | continued growth anticipated 1.

  7. Slide 7: MDCO established and expanding: purpose, vision, mission, goals

    MDCO | established | expanding Our purpose Vision | where we are going We provide leading solutions for leading hospitals Biopharmaceuticals | knowledge | hospital customers | world-class medical | economic | results | acute | intensive care Mission | how we plan to get there Required capabilities F

  8. Slide 8: Angiomax is the growing US market leader in PCI

    MDCO | established | expanding Angiomax is the growing US market leader in percutaneous coronary intervention (PCI) Net revenue: 45% CAGR 2001-9 Volume has driven recent revenue growth Extensive clinical program in PCI Four major randomized trials from SA to STEMI Comparative effectiveness studies E

  9. Slide 9: Continuing to build the Angiomax franchise worldwide

    MDCO | established | expanding Continuing to build the Angiomax franchise worldwide Potential sources of growth: US volume & pricing EU volume growth 40% + p.a. Expanding geography Eastern Europe, Turkey, Russia India Brazil Exploratory work in China Immediate drivers Potential sources of growth: St

  10. Slide 10: Cleviprex is being set up for re-launch in US

    MDCO | established | expanding Cleviprex is being set up for re-launch in US and approval in Germany | UK | Australia Strong formulary adoption during 1st launch year Cleviprex was approved by FDA in 3Q 2008 with a broad label for the treatment of blood pressure when oral agents are not feasible or

  11. Slide 11: Re-launch Cleviprex in US, launch in rest of world

    MDCO | established | expanding Re-launch Cleviprex in US, launch in rest of world Secure high quality supply chain Hospira currently making validation batches for US release Anticipate drug availability 1H 2011 Resume ex-US regulatory process Immediate drivers Refocus brand on neurocritical care Int

  12. Slide 12: Development portfolio value: six products/compounds in addition to Angiomax

    Development | portfolio | value Six products | compounds in addition to Angiomax - a series of major value-drivers expected 2.

  13. Slide 13: Six products/compounds in addition to Angiomax: major value-drivers expected

    Development | portfolio | value Six products | compounds in addition to Angiomax - a series of major value-drivers expected Acute | intensive care products and compounds Anticipated major milestones 2010-2013 Start of CHAMPION PHOENIX phase III trial Start of SOLO phase III trials Start of MDCO-2010

  14. Slide 14: Cangrelor: Phase III iv platelet P2Y12 inhibitor for PCI and ACS

    Development | portfolio | value Cangrelor: Phase III iv platelet P2Y12 inhibitor for PCI and ACS Acute anti-platelet profile Rapid and titrateable onset of action Complete platelet inhibition Recovery of platelet function in 1 hour Clinical effect and safety demonstrated Significant 45% reduction in

  15. Slide 15: Cangrelor: development program considerations

    Development | portfolio | value Cangrelor: Phase III iv platelet P2Y12 inhibitor for PCI and ACS Development program considerations CHAMPION PHOENIX phase III in a PCI population Lessons from the large CHAMPION dataset Universal MI definition No P2Y12 inhibitor prior to randomization Add ARC-defined

  16. Slide 16: Oritavancin: Phase III iv antibiotic for gram-positive infections

    Development | portfolio | value Oritavancin: Phase III iv antibiotic for serious gram-positive infections including MRSA Microbiological profile Rapid bactericidal action Active against clostridium difficile including spores Potential single dose iv treatment to cure MRSA Potentially reduced hospita

  17. Slide 17: Oritavancin: SOLO-1 and SOLO-2 trial design

    Development | portfolio | value Oritavancin: Phase III iv antibiotic for serious gram-positive infections including MRSA Multicenter, double-blind, randomized Single-dose iv oritavancin vs. vancomycin 7-10 days Non-inferiority for the primary efficacy outcome Cessation of spread or reduction in size

  18. Slide 18: MDCO-2010: Phase II iv antifibrinolytic to reduce surgical blood loss

    Development | portfolio | value MDCO-2010: Phase II iv antifibrinolytic to reduce surgical blood loss Targets fibrinolysis and coagulation Primary: plasmin | plasma kallikrein Secondary: factor X | factor XI | aPC Small molecule Liquid ready-to-use formulation Preclinical data, potential to overcome

  19. Slide 19: MDCO-216: Phase 0-I reverse cholesterol transport agent

    Development | portfolio | value MDCO-216: Phase 0-I genetic variant reverse cholesterol transport agent HDL-C is a potent inverse CV risk factor HDL apo A-I is anti-atherosclerotic in animals Human carriers of variant apo A-I Milano Have low levels of HDL-C (0.25-0.78 mmol/L), yet Enjoy less atheros

  20. Slide 20: MDCO-216: renewed interest in HDL

    Development | portfolio | value MDCO-216: Phase 0-I genetic variant reverse cholesterol transport agent CSL-112 (Reconstituted HDL) - CSL ApoA-I Milano/Phospholipid Complex - SemBioSys ATI-5261 - Artery Therapeutics / Roche 5-Ala - NIH / KineMed Cerenis HDL - Cerenis Therapeutics Trimeric A-I - Bore

  21. Slide 21: Leadership, development know-how, commercial focus

    Leadership | development know-how | commercial focus Hospital market knowledge | relationships | record of innovation 3.

  22. Slide 22: MDCO senior leadership

    Know-how | capabilities | depth MDCO senior leadership MDCO has considerable strength, depth and breadth of leadership and continues to build professional competences All five of the founders of the firm has either stayed with MDCO or have returned after periods working in other entities The group h

  23. Slide 23: We design, perform and report influential clinical trials

    Leadership | development know-how | commercial focus We design, perform and report influential clinical trials Trial name Design Patients Principle publication(s) Guidelines Label REPLACE-2 Angiomax vs. heparin + GPIIb/IIIa in planned PCI ~6,000 JAMA Lancet Yes US | EU ACUITY Angiomax vs. heparin +

  24. Slide 24: We concentrate on <3,000 hospitals worldwide

    Leadership | development know-how | commercial focus We concentrate on <3,000 hospitals worldwide More than 80% of acute cardiac care, including PCI, is performed in 2,548 leading hospitals in 26 countries across 14 language zones. These institutions represent our call list. We have mapped their whe

  25. Slide 25: Disciplined financial focus

    Disciplined | financial | focus Strong foundations and planned sustainable growth 4.

  26. Slide 26: Strong foundations and planned sustainable growth

    Disciplined | financial | focus Strong foundations and planned sustainable growth Total net revenue ($M) Cash flow from operations ($M) Generated cash flow ~$245M since 2006 Deal-making & YE cash ($M) Angiox EU Curacyte Angiomax lifecycle Argatroban Targanta MDCO-216 MDCO-2010 milestone 2010 3rd qua

  27. Slide 27: New business ventures activities

    Disciplined | financial | focus New business ventures activities We will continue to focus on acute | intensive care business development opportunities for leading hospitals Cardiovascular | stroke | serious infection Innovative products Low upfront payments Late stage - ideally with low R&D require

  28. Slide 28: Our strategic approach to growth

    Disciplined | financial | focus Our strategic approach to growth Net sales development We believe that Angiomax will continue to grow in US with extended exclusivity through mid 20151 as the results of a combination of volume expansion and price increases linked to the value our health and economic

  29. Slide 29: Unique time to invest in MDCO

    Unique time to invest in MDCO Opportunity to participate in growth of acute | intensive care hospital medicine worldwide 1. Established | expanding | presence Angiomax(r) (bivalirudin) a growing $400M+ franchise in acute hospital arterial anticoagulation 45% CAGR since launch - >3 million PCI patien

Medicines — Investor Presentation (November 2010) on 6ix